--- http_interactions: - request: method: get uri: https://doaj.org/api/v1/search/articles/+cancer?page=3&pageSize=20 body: encoding: UTF-8 string: '' headers: Cookie: - session=UspzkET/3IS3Z8PIxKnLAhLnXDY=?_id=UycyNmYyZmZkMzhkMjA5MWE0NmNjZTU2YTI4OGJjNDZlNycKcDEKLg== response: status: code: 200 message: OK headers: Server: - nginx/1.4.6 (Ubuntu) Date: - Wed, 23 Sep 2015 15:51:27 GMT Content-Type: - application/json Content-Length: - '51877' Connection: - keep-alive Vary: - Accept-Encoding - Accept-Encoding Access-Control-Allow-Origin: - "*" Set-Cookie: - session="UspzkET/3IS3Z8PIxKnLAhLnXDY=?_id=UycyNmYyZmZkMzhkMjA5MWE0NmNjZTU2YTI4OGJjNDZlNycKcDEKLg=="; Path=/; HttpOnly body: encoding: UTF-8 string: '{"pageSize": 20, "timestamp": "2015-0923T15:51:27Z", "results": [{"last_updated": "2015-04-22T03:06:02Z", "id": "82c9dc39aebe429d8e37b55469ed882d", "bibjson": {"identifier": [{"type": "doi", "id": "10.1007/s11805-011-0562-z"}, {"type": "pissn", "id": "2095-3941"}], "start_page": "77", "title": "The Role of Inflammation in Breast Cancer and Prostate Cancer", "journal": {"publisher": "Cancer Biology & Medicine", "language": ["English"], "title": "Cancer Biology & Medicine", "country": "CN", "number": "2", "volume": "8"}, "author": [{"name": "Wen-liang Zhang"}], "month": "06", "link": [{"url": "http://www.cancerbiomed.org/index.php/cocr/article/view/48", "type": "fulltext"}], "year": "2011", "keywords": ["breast cancer", "prostate cancer", "inflammation"], "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}], "abstract": "Inflammatory conditions increase the risk of cancer. Strong evidences showed that inflammation contributes to breast cancer and prostate cancer in different ways such as inflammation-induced DNA or RNA damage, overexpression cytokines, chemokines etc. Recent studies have begun to unravel molecular pathways linking inflammation and cancer. Some possible mechanisms by which inflammation can contribute to carcinogenesis have been found. These mechanisms bywhich inflammation contributes to cancer give broader views of cancer development. These insights are fostering new anti-inflammatory therapeutic approaches to cancer development.", "end_page": "84"}, "created_date": "2013-05-28T04:38:15Z"}, {"last_updated": "2015-04-22T03:40:51Z", "id": "b029e7276dc04946bed67f41e0da3f88", "bibjson": {"title": "Cancer Stem Cells and Epithelial Ovarian Cancer", "journal": {"publisher": "Hindawi Publishing Corporation", "language": ["English"], "license": [{"type": "CC BY", "title": "CC BY"}], "title": "Journal of Oncology", "country": "EG", "volume": "2010"}, "author": [{"name": "Dimitra Dafou"}, {"name": "Sheetal Dyall"}, {"name": "Simon A. Gayther"}], "link": [{"url": "http://dx.doi.org/10.1155/2010/105269", "type": "fulltext"}], "year": "2010", "identifier": [{"type": "doi", "id": "10.1155/2010/105269"}, {"type": "pissn", "id": "1687-8450"}, {"type": "eissn", "id": "1687-8469"}], "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}]}, "created_date": "2011-03-07T15:02:17Z"}, {"last_updated": "2015-04-22T01:56:03Z", "id": "27b89368a80b42219ae2459abb01859c", "bibjson": {"identifier": [{"type": "doi", "id": "10.2298/AOO0403168R"}, {"type": "pissn", "id": "0354-7310"}], "start_page": "168", "title": "Cancer pain syndromes and pharmacotherapy of cancer pain", "journal": {"publisher": "Institute of Oncology Sremska Kamenica", "language": ["English"], "title": "Archive of Oncology", "country": "RS", "number": "3", "volume": "12"}, "author": [{"name": "Ripamonti Carla"}], "link": [{"url": "http://www.doiserbia.nb.rs/img/doi/0354-7310/2004/0354-73100403168R.pdf", "type": "fulltext"}], "year": "2004", "keywords": ["neoplasms", "pain", "drug therapy", "analgesics"], "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}], "end_page": "170"}, "created_date": "2010-10-08T13:28:32Z"}, {"last_updated": "2015-04-22T03:21:53Z", "id": "973ebcc0ac544b758dfac883d2e221b0", "bibjson": {"start_page": "52", "title": "German cancer statistics 2004", "journal": {"publisher": "BioMed Central", "language": ["English"], "license": [{"type": "CC BY", "title": "CC BY"}], "title": "BMC Cancer", "country": "GB", "number": "1", "volume": "10"}, "author": [{"name": "Ziese Thomas"}, {"name": "Wolf Ute"}, {"name": "Bertz Joachim"}, {"name": "Haberland J\u00f6rg"}, {"name": "Kurth B\u00e4rbel-Maria"}], "month": "2", "link": [{"url": "http://www.biomedcentral.com/1471-2407/10/52", "type": "fulltext"}], "year": "2010", "identifier": [{"type": "doi", "id": "10.1186/1471-2407-10-52"}, {"type": "pissn", "id": "1471-2407"}], "abstract": "

Abstract

Background

For years the Robert Koch Institute (RKI) has been annually pooling and reviewing the data from the German population-based cancer registries and evaluating them together with the cause-of-death statistics provided by the statistical offices. Traditionally, the RKI periodically estimates the number of new cancer cases in Germany on the basis of the available data from the regional cancer registries in which registration is complete; this figure, in turn, forms the basis for further important indicators.

Methods

This article gives a brief overview of current indicators - such as incidence, prevalence, mortality, survival rates - on the most common types of cancer, as well as important ratios on the risks of developing and dying of cancer in Germany.

Results

According to the latest estimate, there were a total of 436,500 new cancer cases in Germany in 2004. The most common cancer in men is prostate cancer with over 58,000 new cases per annum, followed by colorectal and lung cancer. In women, breast cancer remains the most common cancer with an estimated 57,000 new cases every year, also followed by colorectal cancer. These and further findings on selected cancer sites can be found in the current brochure on \"Cancer in Germany\", which is regularly published by the RKI together with the Association of Population-based Cancer Registries in Germany (GEKID). In addition, the RKI made cancer-prevalence estimates and calculated current morbidity and mortality risks at the federal level for the first time. According to these figures, the 5-year partial prevalence - i.e. the total number of cancer patients diagnosed over the past five years who are currently still living - exceeds 600,000 in men; the figure is about the same among women. Here, too, the most common cancers are prostate cancer in men and breast cancer in women. The lifetime risk of developing cancer, which is more related to the individual, is estimated to be higher among men (48.5%) than among women (40.3%). In roughly rounded figures, therefore, about every second person in Germany develops cancer in the course of their lives. One in four men and one in five women die of cancer.

Conclusions

In recent years, population-based cancer registration in Germany has come significantly closer to the aim of the complete, nationwide coverage of cancer. The continuous improvements in the data situation help describe cancer development in Germany.

", "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}]}, "created_date": "2010-03-19T00:00:00Z"}, {"last_updated": "2015-04-22T04:39:55Z", "id": "fc05eb22a7dc48e593cb2074bc140a1b", "bibjson": {"identifier": [{"type": "pissn", "id": "0019-509X"}], "start_page": "87", "title": "Positron emission tomography imaging in evaluation of cancer patients.", "journal": {"publisher": "Medknow Publications", "language": ["English"], "title": "Indian Journal of Cancer", "country": "IN", "number": "3", "volume": "40"}, "author": [{"name": "Kumar R"}, {"name": "Bhargava P"}, {"name": "Bozkurt M"}, {"name": "Zhuang H"}, {"name": "Potenta S"}, {"name": "Alavi A"}], "link": [{"url": "http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2003;volume=40;issue=3;spage=87;epage=100;aulast=Kumar", "type": "fulltext"}], "year": "2003", "keywords": ["Positron emission tomography", "Fluorodeoxyglucose", "Lymphoma", "colonic cancer", "Lung nodule and lung cancer", "Breast cancer", "Head and neck cancer", "Ovarian cancer", "Melanoma", "Gastric and esophageal cancer."], "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}], "abstract": "Positron emission tomography (PET) is a diagnostic imaging technique that has progressed rapidly from being a research technique in laboratories to a routine clinical imaging modality. The most widely used radiotracer in PET is Fluorine18-fluorodeoxyglucose (F18-FDG), which is an analogue of glucose. The FDG uptake in cells is directly proportional to glucose metabolism of cells. Since glucose metabolism is increased many fold in malignant tumors PET has a high sensitivity and a high negative predictive value. PET with FDG is now the standard of care in initial staging, monitoring the response to the therapy, and management of lung cancer, colonic cancer, lymphoma, melanoma, esophageal cancer, head and neck cancer and breast cancer. Other indications of PET like bone tumor, ovarian cancer and cancer of unknown primary (CUP) has also been discussed in brief. The aim of this review article is to review the clinical applications of PET in various malignancies and only limited number of important studies will be discussed for this effort.", "end_page": "100"}, "created_date": "2007-04-14T00:00:00Z"}, {"last_updated": "2015-04-22T04:38:00Z", "id": "f978d4678cb9485984658a52aa8420d5", "bibjson": {"start_page": "552", "title": "Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients", "journal": {"publisher": "BioMed Central", "language": ["English"], "license": [{"type": "CC BY", "title": "CC BY"}], "title": "BMC Cancer", "country": "GB", "number": "1", "volume": "12"}, "author": [{"name": "Pelttari Liisa M"}, {"name": "Nurminen Riikka"}, {"name": "Gylfe Alexandra"}, {"name": "Aaltonen Lauri A"}, {"name": "Schleutker Johanna"}, {"name": "Nevanlinna Heli"}], "month": "11", "link": [{"url": "http://www.biomedcentral.com/1471-2407/12/552", "type": "fulltext"}], "year": "2012", "keywords": ["RAD51C", "Prostate cancer", "Colorectal cancer", "Breast cancer", "Ovarian cancer", "Founder mutation"], "identifier": [{"type": "doi", "id": "10.1186/1471-2407-12-552"}, {"type": "pissn", "id": "1471-2407"}], "abstract": "

Abstract

Background

Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not breast cancer in the absence of ovarian cancer. Risk for other cancers has not been studied.

Methods

To study the role of RAD51C mutations in other common cancer types, we genotyped the Finnish RAD51C founder mutations c.837\u2009+\u20091G\u2009>\u2009A and c.93delG in 1083 prostate cancer patients and 802 colorectal cancer patients using TaqMan Real-Time PCR.

Results

No RAD51C mutations c.837\u2009+\u20091G\u2009>\u2009A or c.93delG were detected among the prostate or colorectal cancer patients.

Conclusions

The results suggest that the RAD51C mutations do not predispose to prostate or colorectal cancer.

", "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}]}, "created_date": "2013-03-12T01:30:35Z"}, {"last_updated": "2015-04-22T02:51:03Z", "id": "6fa2255d42074743a7e884afcc4b8546", "bibjson": {"title": "Alteration of pancreatic cancer cell functions by tumor-stromal cell interaction", "journal": {"volume": "4", "country": "CH", "publisher": "Frontiers", "language": ["English"], "title": "Frontiers in Physiology"}, "author": [{"affiliation": "Tohoku University Graduate School of Medicine", "email": "hamadas@med.tohoku.ac.jp", "name": "ShinHamada"}], "month": "11", "link": [{"url": "http://journal.frontiersin.org/Journal/10.3389/fphys.2013.00318/full", "type": "fulltext", "content_type": "html"}], "year": "2013", "keywords": ["Epithelial-Mesenchymal Transition", "Mast Cells", "Pancreatic Stellate Cells", "cancer stem cells", "desmoplasia", "bone marrow derived cells"], "identifier": [{"type": "pissn", "id": "1664-042X"}, {"type": "doi", "id": "10.3389/fphys.2013.00318"}], "abstract": "Pancreatic cancer shows a characteristic tissue structure called desmoplasia, which consists of dense fibrotic stroma surrounding cancer cells. Interactions between pancreatic cancer cells and stromal cells promote invasive growth of cancer cells and establish a specific microenvironment such as hypoxia which further aggravates the malignant behavior of cancer cells. Pancreatic stellate cells (PSCs) play pivotal role in the development of fibrosis within the pancreatic cancer tissue, and also affect the cancer cell functions. PSCs induce epithelial-mesenchymal transition and cancer stem cell (CSC)-related phenotypes in pancreatic cancer cells by activating multiple signaling pathways. In addition, pancreatic cancer cells and PSCs recruit myeloid-derived suppressor cells which attenuate the immune reaction against pancreatic cancer cells. As a result, pancreatic cancer cells become refractory against conventional therapies. The formation of the CSC-niche by stromal cells facilitates postoperative recurrence, re-growth of therapy-resistant tumors and distant metastasis. Conventional therapies targeting cancer cells failed to conquer pancreatic cancer, but targeting stromal cells and immune cells effectively improved the therapeutic responses in experimental conditions. A combination of novel strategies altering stromal cell functions could contribute to improving the pancreatic cancer prognosis. ", "subject": [{"code": "QP1-981", "term": "Physiology", "scheme": "LCC"}, {"code": "Q", "term": "Science", "scheme": "LCC"}, {"code": "QP1-981", "term": "Physiology", "scheme": "LCC"}, {"code": "Q", "term": "Science", "scheme": "LCC"}]}, "created_date": "2014-05-22T09:44:27Z"}, {"last_updated": "2015-04-22T04:34:56Z", "id": "f5782fa584a44c4ca3cc2ead2d06873a", "bibjson": {"title": "Platinum-sensitive recurrence in ovarian cancer: The role of tumor microenvironment", "journal": {"publisher": "Frontiers", "language": ["English"], "license": [{"type": "CC BY", "title": "CC BY"}], "title": "Frontiers in Oncology", "country": "CH", "volume": "3"}, "author": [{"affiliation": "Mayo Clinic College of Medicine", "email": "kuang@cs.umn.edu", "name": "RuiKuang"}], "month": "9", "link": [{"url": "http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00251/full", "type": "fulltext", "content_type": "html"}], "year": "2013", "keywords": ["Extracellular Matrix", "Cancer stem cell", "ovarian cancer", "platinum-sensitive recurrence", "platinum resistance"], "identifier": [{"type": "pissn", "id": "2234-943X"}, {"type": "doi", "id": "10.3389/fonc.2013.00251"}], "abstract": "Despite several advances in the understanding of ovarian cancer pathobiology, in terms of driver genetic alterations in high-grade serous cancer, histology heterogeneity of epithelial ovarian cancer, cell-of-origin for ovarian cancer, the survival rate from ovarian cancer is disappointingly low when compared to that of breast or prostate cancer. One of the factors contributing to the poor survival rate from ovarian cancer is the development of chemotherapy resistance following several rounds of chemotherapy. Although unicellular drug resistance mechanisms contribute to chemotherapy resistance, tumor microenvironment and the extracellular matrix, in particular, is emerging as a significant determinant of a tumor\u2019s response to chemotherapy. In this review, we discuss the potential role of the tumor microenvironment in ovarian cancer recurrence and resistance to chemotherapy. Finally, we propose an alternative view of platinum-sensitive recurrence to describe a potential role of the extracellular matrix in the process. ", "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}]}, "created_date": "2014-05-22T09:49:32Z"}, {"last_updated": "2015-08-03T05:28:29Z", "id": "03f3114aebec453896864b46b07b5979", "bibjson": {"identifier": [{"type": "doi", "id": "10.5958/2319-5886.2015.00100.9"}, {"type": "pissn", "id": "2319-5886"}, {"type": "eissn", "id": "2319-5886"}], "start_page": "519", "title": "A COMPARATIVE STUDY OF CAREGIVER BURDEN IN CANCER CERVIX AND CANCER BREAST ILLNESSES", "abstract": "Background: Caregivers of individuals suffering from cancer illnesses are at risk of having subjected to mental health consequences. There is a paucity of data comparing the caregiver burden of cancer breast and cancer cervix patients. Aim: The aim of the present study is to compare the caregiver burden of cancer breast and cancer cervix patients. To study the association of caregiver burden with demographic factors like age, gender, duration of caregiving etc. Materials & Methods: This Cross sectional study is performed on the key relatives of patients of 31 cancer cervix and 31 cancer breast patients. Burden assessment schedule was used. Results: Our findings suggest burden is more in male caregivers of breast cancer patients. It is not so in caregivers of cancer cervix patients. Whenever the caregiver is closely related to the patients the burden is high in both groups. Whenever the burden scores were high the depression scores were also high. Treatment modalities as a whole correlates with burden scores in caregivers of breast cancer patients but not in cancer cervix patients. Conclusion: Caregivers with breast and cervical cancer patients are vulnerable if the caregiver is male, from low socioeconomical background, more closely related and when the patients received poor treatment modalities.", "author": [{"affiliation": "", "name": "Srinivasagopalan, Nappinnai, Solayappan"}], "month": "7", "link": [{"url": "http://ijmrhs.com/wp-content/plugins/download-attachments/includes/download.php?id=4238", "type": "fulltext"}], "year": "2015", "keywords": ["Burden", "caregiver", "cancer breast"], "end_page": "526", "journal": {"language": ["English"], "license": [{"type": "CC BY-NC-SA", "title": "CC BY-NC-SA"}], "title": "International Journal of Medical Research and Health Sciences", "country": "IN", "number": "3", "volume": "4"}, "subject": [{"code": "A", "term": "General Works", "scheme": "LCC"}]}, "created_date": "2015-08-03T05:28:29Z"}, {"last_updated": "2015-04-22T03:37:55Z", "id": "ac4e51bd6f464828a5859b0731f49ced", "bibjson": {"start_page": "A42", "title": "An audit of families with unreported or misreported cancers verified through a population-based cancer registry: implications for providing cancer risk assessment and management advice by a Familial Cancer Centre", "journal": {"publisher": "BioMed Central", "language": ["English"], "license": [{"type": "CC BY", "title": "CC BY"}], "title": "Hereditary Cancer in Clinical Practice ", "country": "GB", "number": "Suppl 2", "volume": "10"}, "author": [{"name": "Kentwell M"}, {"name": "Bogwitz M"}, {"name": "Donoghue L"}, {"name": "McArdle T"}], "month": "4", "link": [{"url": "http://www.hccpjournal.com/content/10/S2/A42", "type": "fulltext"}], "year": "2012", "identifier": [{"type": "doi", "id": "10.1186/1897-4287-10-S2-A42"}, {"type": "pissn", "id": "1897-4287"}], "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}]}, "created_date": "2013-03-12T11:28:12Z"}, {"last_updated": "2015-04-22T03:17:54Z", "id": "9211366b848e4bf59cb2823168046b79", "bibjson": {"identifier": [{"type": "pissn", "id": "0019-509X"}], "start_page": "139", "title": "The relevance of cervical cancer screening and the future of cervical cancer control in India in the light of the approval of the vaccine against cervical cancer", "journal": {"publisher": "Medknow Publications", "language": ["English"], "title": "Indian Journal of Cancer", "country": "IN", "number": "3", "volume": "43"}, "author": [{"name": "Basu M"}], "link": [{"url": "http://www.bioline.org.br/request?06023", "type": "fulltext"}], "year": "2006", "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}], "end_page": "139"}, "created_date": "2006-11-17T00:00:00Z"}, {"last_updated": "2015-04-22T02:04:16Z", "id": "32930792261249ebbf3805fa7fa7ca06", "bibjson": {"identifier": [{"type": "doi", "id": "10.1007/s11805-011-0584-6"}, {"type": "pissn", "id": "2095-3941"}], "start_page": "220", "title": "Multi-Targeted Therapies in Non-Small Cell Lung Cancer", "journal": {"publisher": "Cancer Biology & Medicine", "language": ["English"], "title": "Cancer Biology & Medicine", "country": "CN", "number": "4", "volume": "8"}, "author": [{"name": "Kai WANG"}, {"name": "Jin WEI"}], "month": "12", "link": [{"url": "http://www.cancerbiomed.org/index.php/cocr/article/view/31", "type": "fulltext"}], "year": "2011", "keywords": ["multi-targeted therapies", "non-small cell lung cancer"], "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}], "abstract": "Current treatment modalities provide limitedimprovement in the natural course of lung cancer, and prognosisremains poor. Lung cancer is a malignancy with great molecularheterogeneity. The complexity of the signaling process leading tocancer cell proliferation and to the neoplastic phenotype supportsthe necessity of interfering at different stages to avoid cancer cellresistance to therapy. For this reason, new strategies for thesimultaneous inhibition of multiple molecular targets are beingpursued.", "end_page": "223"}, "created_date": "2013-05-10T09:22:54Z"}, {"last_updated": "2015-04-22T02:46:12Z", "id": "6956736037c84de3b74c82921eafa553", "bibjson": {"identifier": [{"type": "doi", "id": "10.3390/cancers2041830"}, {"type": "pissn", "id": "2072-6694"}], "start_page": "1830", "title": "Pancreatic Cancer Biomarkers and Their Implication in Cancer Diagnosis and Epidemiology", "journal": {"publisher": "Molecular Diversity Preservation International", "language": ["English"], "license": [{"type": "CC BY", "title": "CC BY"}], "title": "Cancers", "country": "CH", "number": "4", "volume": "2"}, "author": [{"name": "Mukesh Verma"}], "month": "11", "link": [{"url": "http://www.mdpi.com/2072-6694/2/4/1830/", "type": "fulltext"}], "year": "2010", "keywords": ["biomarker", "cancer", "diagnosis", "epidemiology", "epigenetics", "glycans", "methylation index", "pancreas", "prognosis", "sensitivity", "specificity", "survival", "treatment"], "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}], "abstract": "Pancreatic cancer is the fourth most common cause of cancer-related mortality in the United States. Biomarkers are needed to detect this cancer early during the disease development and for screening populations to identify those who are at risk. In cancer, \u201cbiomarker\u201d refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker might be either a molecule secreted by a tumor or it can be a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. A number of potential biomarkers have been identified for pancreatic cancer. These markers can be assayed in non-invasively collected biofluids. These biomarkers need analytical and clinical validation so that they can be used for the purpose of screening and diagnosing pancreatic cancer and determining disease prognosis. In this article, the latest developments in pancreatic cancer biomarkers are discussed. ", "end_page": "1837"}, "created_date": "2010-11-08T17:41:19Z"}, {"last_updated": "2015-04-22T03:29:01Z", "id": "a0af6fc8a0e14324afe2bc68cf9033d1", "bibjson": {"identifier": [{"type": "pissn", "id": "1837-9664"}], "start_page": "503", "title": "Cavitary Lung Cancer Lined with Normal Bronchial Epithelium and Cancer Cells", "journal": {"publisher": "Ivyspring International Publisher", "language": ["English"], "license": [{"type": "CC BY-NC-ND", "title": "CC BY-NC-ND"}], "title": "Journal of Cancer", "country": "AU", "number": "1", "volume": "2"}, "author": [{"name": "Taichiro Goto, Arafumi Maeshima, Yoshitaka Oyamada, Ryoichi Kato"}], "link": [{"url": "http://www.jcancer.org/v02p0503.htm", "type": "fulltext"}], "year": "2011", "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}], "abstract": "

Reports of cavitary lung cancer are not uncommon, and the cavity generally contains either dilated bronchi or cancer cells. Recently, we encountered a surgical case of cavitary lung cancer whose cavity tended to enlarge during long-term follow-up, and was found to be lined with normal bronchial epithelium and adenocarcinoma cells.

", "end_page": "506"}, "created_date": "2011-12-23T12:51:13Z"}, {"last_updated": "2015-04-22T03:10:27Z", "id": "885a4bff30424964a24f39cc76e59e0a", "bibjson": {"start_page": "557", "title": "Mode of primary cancer detection as an indicator of screening practice for second primary cancer in cancer survivors: a nationwide survey in Korea", "journal": {"publisher": "BioMed Central", "language": ["English"], "license": [{"type": "CC BY", "title": "CC BY"}], "title": "BMC Cancer", "country": "GB", "number": "1", "volume": "12"}, "author": [{"name": "Suh Beomseok"}, {"name": "Shin Dong"}, {"name": "Kim So"}, {"name": "Park Jae-Hyun"}, {"name": "Chang Weon"}, {"name": "Lim Seung"}, {"name": "Yim Chang-Yeol"}, {"name": "Cho Be-Long"}, {"name": "Park Eun-Cheol"}, {"name": "Park Jong-Hyock"}], "month": "11", "link": [{"url": "http://www.biomedcentral.com/1471-2407/12/557", "type": "fulltext"}], "year": "2012", "keywords": ["Cancer survivor", "Second primary cancer", "Screening", "Mode of detection", "Screen-detected"], "identifier": [{"type": "doi", "id": "10.1186/1471-2407-12-557"}, {"type": "pissn", "id": "1471-2407"}], "abstract": "

Abstract

Background

While knowledge and risk perception have been associated with screening for second primary cancer (SPC), there are no clinically useful indicators to identify who is at risk of not being properly screened for SPC. We investigated whether the mode of primary cancer detection (i.e. screen-detected vs. non-screen-detected) is associated with subsequent completion of all appropriate SPC screening in cancer survivors.

Methods

Data were collected from cancer patients treated at the National Cancer Center and nine regional cancer centers across Korea. A total of 512 cancer survivors older than 40, time since diagnosis more than 2 years, and whose first primary cancer was not advanced or metastasized were selected. Multivariate logistic regression was used to examine factors, including mode of primary cancer detection, associated with completion of all appropriate SPC screening according to national cancer screening guidelines.

Results

Being screen-detected for their first primary cancer was found to be significantly associated with completion of all appropriate SPC screening (adjusted odds ratio, 2.13; 95% confidence interval, 1.36\u20133.33), after controlling for demographic and clinical variables. Screen-detected cancer survivors were significantly more likely to have higher household income, have other comorbidities, and be within 5 years since diagnosis.

Conclusions

The mode of primary cancer detection, a readily available clinical information, can be used as an indicator for screening practice for SPC in cancer survivors. Education about the importance of SPC screening will be helpful particularly for cancer survivors whose primary cancer was not screen-detected.

", "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}]}, "created_date": "2013-03-12T01:30:43Z"}, {"last_updated": "2015-04-22T03:30:50Z", "id": "a3058decc18d4c3ab5e9b6a101da00c5", "bibjson": {"start_page": "4", "title": "Ovarian cancer: emerging concept on cancer stem cells", "journal": {"publisher": "BioMed Central", "language": ["English"], "license": [{"type": "CC BY", "title": "CC BY"}], "title": "Journal of Ovarian Research ", "country": "GB", "number": "1", "volume": "1"}, "author": [{"name": "Ponnusamy Moorthy P"}, {"name": "Batra Surinder K"}], "month": "10", "link": [{"url": "http://www.ovarianresearch.com/content/1/1/4", "type": "fulltext"}], "year": "2008", "identifier": [{"type": "doi", "id": "10.1186/1757-2215-1-4"}, {"type": "pissn", "id": "1757-2215"}], "abstract": "

Abstract

Emerging evidence suggests that the capacity of a tumor to grow and propagate is dependent on a small subset of cells within a tumor, termed cancer stem cells. In fact, cancer cells, like stem cells, can proliferate indefinitely through a dysregulated cellular self-renewal capacity. Cancer stem cells may originate due to the distribution into self-renewal and differentiation pathways occurring in multi-potential stem cells, tissue-specific stem cells, progenitor cells and cancer cells. Recent studies have shown that ovarian cancer also contains stem cells or tumor-initiating cells. Moreover, ovarian serous adenocarcinomas were disaggregated and subjected to growth conditions to select for self-renewing, non-adherent spheroids previously shown to be derived from tissue stem cells. A recent study showed that epithelial ovarian cancer was derived from a sub population of CD44+, CD117+ and CD133+ cells. The existence of cancer stem cells would explain why only a small minority of cancer cells is capable of extensive proliferation of the tumor. In this review, we have discussed the studies on ovarian cancer stem cells along with the molecular pathways that could be involved in these cancer stem cells.

", "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"term": "Oncology", "scheme": "DOAJ"}, {"term": "Medicine (General)", "scheme": "DOAJ"}, {"term": "Health Sciences", "scheme": "DOAJ"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}, {"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}]}, "created_date": "2013-03-12T10:43:05Z"}, {"last_updated": "2015-08-04T06:02:34Z", "id": "c45f789380c84b7fbeab41d62ea29527", "bibjson": {"identifier": [{"type": "pissn", "id": "0019-509X"}, {"type": "eissn", "id": "1998-4774"}, {"type": "doi", "id": "10.4103/0019-509X.82871"}], "start_page": "145", "title": "Cetuximab in head and neck cancer", "journal": {"publisher": "Medknow Publications", "language": ["English"], "title": "Indian Journal of Cancer", "country": "IN", "number": "2", "volume": "48"}, "author": [{"name": "P M Parikh"}, {"name": "G S Bhattacharyya"}, {"name": "A Vora"}], "link": [{"url": "http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2011;volume=48;issue=2;spage=145;epage=147;aulast=Parikh", "type": "fulltext", "content_type": "html"}], "year": "2011", "end_page": "147", "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}]}, "created_date": "2011-09-09T00:00:00Z"}, {"last_updated": "2015-08-04T06:01:22Z", "id": "48f9ed5ffade434e81f7d48d7596c06d", "bibjson": {"identifier": [{"type": "pissn", "id": "0019-509X"}, {"type": "eissn", "id": "1998-4774"}, {"type": "doi", "id": "10.4103/0019-509X.64704"}], "start_page": "344", "title": "Cervical cancer screening in developing countries", "journal": {"publisher": "Medknow Publications", "language": ["English"], "title": "Indian Journal of Cancer", "country": "IN", "number": "3", "volume": "47"}, "author": [{"name": "S Patra"}, {"name": "D Panda"}], "link": [{"url": "http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2010;volume=47;issue=3;spage=344;epage=345;aulast=Patra", "type": "fulltext", "content_type": "html"}], "year": "2010", "end_page": "345", "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}]}, "created_date": "2010-07-23T00:00:00Z"}, {"last_updated": "2015-08-04T05:30:03Z", "id": "0710f1ff7e564b5a96daa7a7603ceb59", "bibjson": {"identifier": [{"type": "pissn", "id": "0019-509X"}, {"type": "eissn", "id": "1998-4774"}, {"type": "doi", "id": "10.4103/0019-509X.48588"}], "start_page": "1", "title": "Tackling the cancer Tsunami", "journal": {"publisher": "Medknow Publications", "language": ["English"], "title": "Indian Journal of Cancer", "country": "IN", "number": "1", "volume": "46"}, "author": [{"name": "P Kumar"}, {"name": "G S Bhattacharyya"}, {"name": "S Dattatreya"}, {"name": "H Malhotra"}], "link": [{"url": "http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2009;volume=46;issue=1;spage=1;epage=4;aulast=Kumar", "type": "fulltext", "content_type": "html"}], "year": "2009", "end_page": "4", "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}]}, "created_date": "2009-04-12T00:00:00Z"}, {"last_updated": "2015-08-04T06:01:04Z", "id": "f82a22f9acac4852bdf483a9b8ca4f0e", "bibjson": {"identifier": [{"type": "pissn", "id": "0019-509X"}, {"type": "eissn", "id": "1998-4774"}, {"type": "doi", "id": "10.4103/0019-509X.63015"}], "start_page": "231", "title": "Swine flu: High mortality in cancer patients", "journal": {"publisher": "Medknow Publications", "language": ["English"], "title": "Indian Journal of Cancer", "country": "IN", "number": "2", "volume": "47"}, "author": [{"name": "V Wiwanitkit"}], "link": [{"url": "http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2010;volume=47;issue=2;spage=231;epage=231;aulast=Wiwanitkit", "type": "fulltext", "content_type": "html"}], "year": "2010", "end_page": "231", "subject": [{"code": "RC254-282", "term": "Neoplasms. Tumors. Oncology. Including cancer and carcinogens", "scheme": "LCC"}, {"code": "RC31-1245", "term": "Internal medicine", "scheme": "LCC"}, {"code": "R", "term": "Medicine", "scheme": "LCC"}]}, "created_date": "2010-06-18T00:00:00Z"}], "query": "+cancer", "total": 65140, "page": 3}' http_version: recorded_at: Wed, 23 Sep 2015 15:51:27 GMT recorded_with: VCR 2.9.3